Loading clinical trials...

Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults | Clinical Trials | Clareo Health

COMPLETEDPHASE1

Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults

A Single Center, Randomized, Single-blind, Active Comparator Phase 1 Clinical Trial to Assess the Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults

NCT04830358•EuBiologics Co.,Ltd

View on ClinicalTrials.gov

Summary

The safety and immunogenicity of EuPCV15 compared to Prevenar13 are assessed in healthy adults.

Eligibility

Age

19 - 50 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Healthy adults aged 19 to 50 years old
•2. Participants willing to give written informed consent to participate in the trial

Exclusion Criteria

•1. History of invasive pneumococcal infection within 5 years at screening
•2. Known hypersensitivity to any component of the study vaccine
•3. Immune deficiency or immunosuppressive disorder
•4. Immunized with any licensed vaccine within 4 weeks prior to screening
•5. Pregnant, lactating women or women of childbearing age not using a reliable method of contraception
•6. Participants who in the opinion of the investigator will not be able to comply with any of the protocol required procedure

Locations (1)

The Catholic University of Seoul St.Mary's Hospital

Seoul, South Korea

Key Dates

Start Date

May 28, 2020

Primary Completion Date

August 14, 2020

Completion Date

February 1, 2021

Last Updated

October 7, 2021

Enrollment

ACTUAL participants

Conditions

Pneumococcal Disease

Interventions

EuPCV15

BIOLOGICAL

Prevenar13

BIOLOGICAL

Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15

NCT06731374

Pneumococcal DiseasePneumococcal Carriage

View study

RECRUITINGPHASE3

A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People

NCT06044077

Pneumococcal Disease

View study

ACTIVE_NOT_RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 7, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety and Immunogenicity of the 'EuPCV15' in Healthy Korean Adults

Inclusion Criteria

Exclusion Criteria

Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15

A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy People

Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants

Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)

A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan